Advertisement

It's the Cholesterol, Stupid!

      During the 1992 presidential campaign in the United States, the Clinton campaign slogan was “It's the economy, stupid” and that phrase apparently was helpful in getting Mr. Clinton elected president. Several recent publications have been highly critical of some lipid-lowering trials using statin drugs and have debased the cholesterol “hypothesis” on atherosclerosis.
      • Green L.A.
      Cholesterol-lowering therapy for primary prevention: still much we don't know.
      • Ray K.K.
      • Seshasai S.R.
      • Erqou S.
      • Sever P.
      • Jukema J.W.
      • Ford I.
      • Sattar N.
      Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.
      • de Lorgeril M.
      • Salen P.
      • Abramson J.
      • Dodin S.
      • Hamazaki T.
      • Kostucki W.
      • Okuyama H.
      • Pavy B.
      • Rabaeus M.
      Cholesterol lowering, cardiovascular diseases, and the rosuvastatin–JUPITER controversy: a critical reappraisal.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Green L.A.
        Cholesterol-lowering therapy for primary prevention: still much we don't know.
        Arch Intern Med. 2010; 170: 1007-1008
        • Ray K.K.
        • Seshasai S.R.
        • Erqou S.
        • Sever P.
        • Jukema J.W.
        • Ford I.
        • Sattar N.
        Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.
        Arch Intern Med. 2010; 170: 1024-1031
        • de Lorgeril M.
        • Salen P.
        • Abramson J.
        • Dodin S.
        • Hamazaki T.
        • Kostucki W.
        • Okuyama H.
        • Pavy B.
        • Rabaeus M.
        Cholesterol lowering, cardiovascular diseases, and the rosuvastatin–JUPITER controversy: a critical reappraisal.
        Arch Intern Med. 2010; 170: 1032-1036
        • Roberts W.C.
        Atherosclerotic risk factors: are there ten or is there only one?.
        Am J Cardiol. 1989; 64: 552-554
        • Roberts W.C.
        Atherosclerosis: its cause and its prevention.
        Am J Cardiol. 2006; 98: 1550-1555
        • Steinberg D.
        The Cholesterol Wars.
        in: Elsevier, Amsterdam2007: 227
        • Truswell A.S.
        Cholesterol and Beyond.
        in: Springer, Sydney2010: 227
        • Keys A.
        Seven Countries.
        in: Harvard University Press, Cambridge, MA1980: 381
        • Verschurer W.M.
        • Jacobs D.R.
        • Bloemberg B.P.
        • Kromhout D.
        • Menotti A.
        • Aravanis C.
        • Blackburn H.
        • Buzina R.
        • Dontas A.S.
        • Fidanza F.
        Serum total cholesterol and long-term coronary heart disease in different cultures.
        JAMA. 1995; 274: 131-136
      1. Kromhout D. Menotti A. Blackburn H. The Seven Countries Study: A Scientific Adventure in Cardiovascular Disease Epidemiology. Marjan Nijssen-Kramer, Bilthoven, The Netherlands1993: 219
        • Anitschkow N.N.
        A history of experimentation on arterial atherosis in animals.
        in: Blumenthal H.T. Cowdry's Arteriosclerosis A Survey of the Problem. Charles C Thomas, Springfield, IL1967: 21-44
        • Kannel W.B.
        • Dawber T.R.
        • Kagan A.
        • Revotskie N.
        • Stokes III, J.
        Factors of risk in the development of coronary heart disease—six year follow-up experience.
        Ann Intern Med. 1961; 55: 33-50
        • Kannel W.B.
        • Castelli W.P.
        • Gordon T.
        Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study.
        Ann Intern Med. 1979; 90: 85-89
        • Mautner S.L.
        • Sanchez J.A.
        • Rader D.J.
        • Mautner G.C.
        • Ferrans V.J.
        • Fredrickson D.S.
        • Brewer Jr, H.B.
        • Roberts W.C.
        The heart in Tangier disease: severe coronary atherosclerosis with near absence of high-density lipoprotein cholesterol.
        Am J Clin Pathol. 1992; 98: 191-198
        • Libby P.
        • Ridker P.M.
        • Maseri A.
        Inflammation and atherosclerosis.
        Circulation. 2002; 105: 1135-1143
        • Roberts W.C.
        Qualitative and quantitative comparison of amounts of narrowing by atherosclerotic plaques in the major epicardial coronary arteries at necropsy in sudden coronary death, transmural acute myocardial infarction, transmural healed myocardial infarction and unstable angina pectoris.
        Am J Cardiol. 1989; 64: 324-328
        • Roberts W.C.
        • Turnage II, T.A.
        • Whiddon L.L.
        Quantitative comparison of amounts of cross-sectional area narrowing in coronary endarterectomy specimens in patients having coronary artery bypass grafting to amounts of narrowing in the same artery in patients with fatal coronary artery disease studied at necropsy.
        Am J Cardiol. 2007; 99: 588-592
        • Sprecher D.L.
        • Schaefer E.J.
        • Kent K.M.
        • Gregg R.E.
        • Zech L.A.
        • Hoeg J.M.
        • McManus B.
        • Roberts W.C.
        • Brewer Jr, H.B.
        Cardiovascular features of homozygous familial hypercholesterolemia: analysis of 16 patients.
        Am J Cardiol. 1984; 54: 20-30
        • Grundy S.M.
        • Cleeman J.L.
        • Merz C.N.
        • Brewer Jr, H.B.
        • Clark L.T.
        • Hunninhake D.B.
        • Pasternak R.C.
        • Smith Jr, S.C.
        • Stone N.J.
        • Coordinating Committee of the National Cholesterol Education Program
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
        Circulation. 2004; 110: 227-239
        • Roberts W.C.
        The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease.
        Am J Cardiol. 1996; 78: 377-378
        • Roberts W.C.
        Shifting from decreasing risk to actually preventing and arresting atherosclerosis.
        Am J Cardiol. 1999; 83: 816-817

      Linked Article

      • More Reasons Statin Drugs Are Shunned
        American Journal of CardiologyVol. 107Issue 6
        • Preview
          In his November 1 editorial, Roberts1 persuasively summarized the line of evidence supporting serum cholesterol elevation as the essential cause of atherosclerosis and therefore as the dominant factor responsible for cardiovascular events. The editor then listed potential reasons why the role of cholesterol is frequently minimized. Chief among them is the emphasis on multiple atherosclerotic risk factors, which distracts from the proper clinical focus on cholesterol and potentially limits broader use of statin drugs.
        • Full-Text
        • PDF